<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2393-6797</journal-id>
<journal-title><![CDATA[Revista Uruguaya de Medicina Interna ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Urug. Med. Int.]]></abbrev-journal-title>
<issn>2393-6797</issn>
<publisher>
<publisher-name><![CDATA[Sociedad de Medicina Interna del Uruguay]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2393-67972023000100026</article-id>
<article-id pub-id-type="doi">10.26445/08.01.3</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Uso de NT-proBNP en el seguimiento ambulatorio de pacientes con insuficiencia cardiaca con fracción de eyección del ventrículo izquierdo reducida en una unidad multidisciplinaria de insuficiencia cardiaca.]]></article-title>
<article-title xml:lang="en"><![CDATA[Use of NT-proBNP in the outpatient follow-up of heart failure patients with reduced left ventricular ejection fraction in a multidisciplinary heart failure unit.]]></article-title>
<article-title xml:lang="pt"><![CDATA[Uso do NT-proBNP no acompanhamento ambulatorial de pacientes com insuficiência cardíaca com fração de ejeção do ventrículo esquerdo reduzida em uma unidade multidisciplinar de insuficiência cardíaca.]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Valdivieso]]></surname>
<given-names><![CDATA[Carlos Guamán]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bueno Prato]]></surname>
<given-names><![CDATA[Luis Emiro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García Rojas]]></surname>
<given-names><![CDATA[Zulay Andrea]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Álvarez Rocha]]></surname>
<given-names><![CDATA[Pablo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Florio Legnani]]></surname>
<given-names><![CDATA[Lucía]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ormaechea Gorricho]]></surname>
<given-names><![CDATA[Gabriela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de la República Facultad de Medicina Unidad Multidisciplinaria de Insuficiencia Cardíaca (UMIC) Clínica Médica A Hospital de Clínicas &#8220;Dr. Manuel Quintela]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Uruguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2023</year>
</pub-date>
<volume>8</volume>
<numero>1</numero>
<fpage>26</fpage>
<lpage>37</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S2393-67972023000100026&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S2393-67972023000100026&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S2393-67972023000100026&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  La insuficiencia cardíaca (IC) es un síndrome clínico prevalente a nivel mundial, que se beneficia del abordaje multidisciplinario, pero su seguimiento ambulatorio sigue siendo un reto. La utilidad diagnóstica y pronóstica del NT-proBNP está apoyada en la evidencia actual; pero su uso en el seguimiento aún no ha sido definido. En el presente estudio se busca determinar si la variación en el tiempo del valor de NT-proBNP se relacionó con modificación en el tratamiento farmacológico de pacientes ambulatorios con IC y fracción de eyección del ventrículo izquierdo reducida (FEVI &#8804; 40%) de una unidad multidisciplinaria de insuficiencia cardíaca (UMIC).  Metodología:  Estudio cohorte retrospectivo, de pacientes que cumplieron con los criterios de inclusión: 2 o más cuantificaciones de NT-proBNP en 12 meses y un seguimiento mínimo de 2 años entre los años 2013 y 2017.  Resultados:  De un total de 566 sujetos integrantes de cohorte activa de UMIC se incluyeron 107 que cumplieron criterios de inclusión; la mayoría hombres (58%), edad mediana de 63 años (Q1;Q3: 55,9;71,2 años), la principal comorbilidad fue hipertensión arterial (71%). En 56% de la población la etiología de IC fue no isquémica y el 50% tenía una clase funcional - NYHA I. La mediana de NT-proBNP basal fue de 698 pg/ml (Q1;Q3: (218;1564 pg/ml), con FEVI basal mediana de 30% (Q1;Q3: 27%;40%). En 55% de los pacientes la variación del valor de NT-proBNP durante el seguimiento se relacionó con modificaciones en el tratamiento farmacológico.  Conclusiones:  En la mitad de la población de nuestra cohorte se evidenció que los valores de NT-proBNP se relacionaron con cambios en el tratamiento farmacológico, independientemente de la situación clínica.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  Heart failure (HF) is a prevalent clinical syndrome worldwide, which benefits from a multidisciplinary approach, but its outpatient follow-up remains a challenge. The diagnostic and prognostic utility of NT-proBNP is supported by current evidence, but its use in monitoring has not yet been defined. The present study sought to determine whether the variation over time in the value of NT-proBNP was related to changes in the pharmacological treatment of outpatients with HF and reduced left ventricular ejection fraction (LVEF &#8804; 40%) in a multidisciplinary heart failure unit. (MHFU).  Methodology:  Retrospective cohort study of patients, who met the inclusion criteria: 2 or more quantifications of NT-proBNP in 12 months and a minimum follow-up of 2 years between 2013 and 2017.  Results:  Of 566 members of the MHFU active cohort, 107 met the inclusion criteria; most men (58%), median age 63 years (Q1;Q3: 55.9;71.2), the main comorbidity was arterial hypertension (71%). The etiology of HF was non-ischemic in 56% of the population, and 50% had a functional class - NYHA I. Median baseline NT-proBNP was 698 pg/ml (Q1;Q3: (218;1564), with median baseline LVEF of 30% (Q1;Q3: 27;40). In 55% of the patients, the variation in the NT-proBNP value during follow-up was related to changes in pharmacological treatment.  Conclusions:  In half of the population of our cohort, it was shown that NT-proBNP values were related to changes in pharmacological treatment, regardless of the clinical situation.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Introdução:  A insuficiência cardíaca (IC) é uma síndrome clínica prevalente em todo o mundo, que se beneficia de uma abordagem multidisciplinar, mas seu acompanhamento ambulatorial continua sendo um desafio. A utilidade diagnóstica e prognóstica do NT-proBNP é suportada pelas evidências atuais, mas seu uso no monitoramento ainda não foi definido. O presente estudo procurou determinar se a variação ao longo do tempo no valor do NT-proBNP estava relacionada a mudanças no tratamento farmacológico de pacientes ambulatoriais com IC e fração de ejeção do ventrículo esquerdo (FEVE &#8804; 40%) reduzida em uma unidade multidisciplinar de insuficiência cardíaca. (UMIC).  Metodologia:  Estudo de coorte retrospectivo de pacientes que preencheram os critérios de inclusão: 2 ou mais quantificações de NT-proBNP em 12 meses e seguimento mínimo de 2 anos entre 2013 e 2017.  Resultados:  Dos 566 membros da coorte ativa do UMIC, 107 preencheram os critérios de inclusão; maioria dos homens (58%), idade mediana 63 anos (Q1;Q3: 55,9;71,2), a principal comorbidade foi hipertensão arterial (71%). A etiologia da IC foi não-isquêmica em 56% da população, e 50% tinham classe funcional - NYHA I. A mediana basal do NT-proBNP foi de 698 pg/ml (Q1;Q3: (218;1564), com mediana basal FEVE de 30% (Q1;Q3: 27;40). Em 55% dos pacientes, a variação do valor de NT-proBNP durante o seguimento esteve relacionada a mudanças no tratamento farmacológico.  Conclusões:  Em metade da população do nosso coorte, foi demonstrado que os valores de NT-proBNP estavam relacionados a mudanças no tratamento farmacológico, independentemente da situação clínica.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[insuficiencia cardíaca]]></kwd>
<kwd lng="es"><![CDATA[unidad multidisciplinaria]]></kwd>
<kwd lng="es"><![CDATA[péptidos natriuréticos]]></kwd>
<kwd lng="es"><![CDATA[NT-ProBNP]]></kwd>
<kwd lng="en"><![CDATA[heart failure]]></kwd>
<kwd lng="en"><![CDATA[multidisciplinary unit]]></kwd>
<kwd lng="en"><![CDATA[natriuretic peptides]]></kwd>
<kwd lng="en"><![CDATA[NT-ProBNP]]></kwd>
<kwd lng="pt"><![CDATA[insuficiência cardíaca]]></kwd>
<kwd lng="pt"><![CDATA[unidade multidisciplinar]]></kwd>
<kwd lng="pt"><![CDATA[peptídeos natriuréticos]]></kwd>
<kwd lng="pt"><![CDATA[NT-ProBNP]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ponikowski]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Voors]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Anker]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Bueno]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Cleland]]></surname>
<given-names><![CDATA[JGF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC]]></article-title>
<collab>Coats AJS et al</collab>
<source><![CDATA[Eur J Heart Fail]]></source>
<year>2016</year>
<volume>18</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>891-975</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McKee]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Castelli]]></surname>
<given-names><![CDATA[WP]]></given-names>
</name>
<name>
<surname><![CDATA[McNamara]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Kannel]]></surname>
<given-names><![CDATA[WB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The natural history of congestive heart failure the Framingham study]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1971</year>
<volume>285</volume>
<numero>26</numero>
<issue>26</issue>
<page-range>1441-6</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rich]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology, pathophysiology, and prognosis of heart failure in the elderly]]></article-title>
<source><![CDATA[Clin Geriatr Med]]></source>
<year>2007</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[King]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kingery]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Casey]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and evaluation of heart failure]]></article-title>
<source><![CDATA[Am Fam Physician]]></source>
<year>2012</year>
<volume>85</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1161-8</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gheorghiade]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vaduganathan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fonarow]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Bonow]]></surname>
<given-names><![CDATA[RO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rehospitalization for heart failure problems and perspectives]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2013</year>
<volume>61</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>391-403</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pascual-Figal]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Casademont]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lobos]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Piñera]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bayés-Genis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ordóñez-Llanos]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consensus document and recommendations on the use of natriuretic peptides in clinical practice]]></article-title>
<source><![CDATA[Rev Clin Esp (Barc)]]></source>
<year>2016</year>
<volume>216</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>313-22</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yancy]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
<name>
<surname><![CDATA[Jessup]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bozkurt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Butler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Casey Jr]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Colvin]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2017</year>
<volume>136</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>e137-61</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McDonagh]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Metra]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Adamo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gardner]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Baumbach]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Böhm]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2021</year>
<volume>42</volume>
<numero>36</numero>
<issue>36</issue>
<page-range>3599-726</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Savarese]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Musella]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[D&amp;apos;Amore]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Vassallo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Losco]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Gambardella]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure a meta-analysis]]></article-title>
<source><![CDATA[JACC Heart Fail]]></source>
<year>2014</year>
<volume>2</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>148-58</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Felker]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Anstrom]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Adams]]></surname>
<given-names><![CDATA[KF]]></given-names>
</name>
<name>
<surname><![CDATA[Ezekowitz]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Fiuzat]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Houston-Miller]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction A Randomized Clinical Trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2017</year>
<volume>318</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>713-20</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Potter]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
<name>
<surname><![CDATA[Yoder]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Flora]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Antos]]></surname>
<given-names><![CDATA[LK]]></given-names>
</name>
<name>
<surname><![CDATA[Dickey]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Natriuretic peptides their structures, receptors, physiologic functions and therapeutic applications]]></article-title>
<source><![CDATA[Handb Exp Pharmacol]]></source>
<year>2009</year>
<numero>191</numero>
<issue>191</issue>
<page-range>341-66</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nakagawa]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Nishikimi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kuwahara]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atrial and brain natriuretic peptides Hormones secreted from the heart]]></article-title>
<source><![CDATA[Peptides]]></source>
<year>2019</year>
<volume>111</volume>
<page-range>18-25</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Howie]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
<name>
<surname><![CDATA[Caldwell]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Dracup]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The measurement of brain natriuretic peptide in heart failure precision, accuracy, and implications for practice]]></article-title>
<source><![CDATA[AACN Clin Issues]]></source>
<year>2003</year>
<volume>14</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>520-31</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González-González]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[Lobos-Bejarano]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Horrillo-García]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Castellanos-Maroto]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz-Sánchez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Castellanos-Rodríguez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Péptido cerebral natriurético Valor diagnóstico en la insuficiencia cardíaca]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2002</year>
<volume>55</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>7-15</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cowie]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Jourdain]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Maisel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dahlstrom]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Follath]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Isnard]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical applications of B-type natriuretic peptide (BNP) testing]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2003</year>
<volume>24</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>1710-8</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Yoon]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Oh]]></surname>
<given-names><![CDATA[IY]]></given-names>
</name>
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2015</year>
<volume>101</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>1881-8</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vader]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Drazner]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical assessment of heart failure utility of symptoms, signs, and daily weights]]></article-title>
<source><![CDATA[Heart Fail Clin]]></source>
<year>2009</year>
<volume>5</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>149-60</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fonseca]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Morais]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Mota]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Matias]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gouveia-Oliveira]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The diagnosis of heart failure in primary care value of symptoms and signs]]></article-title>
<source><![CDATA[Eur J Heart Fail]]></source>
<year>2004</year>
<volume>6</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>795-822</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Acle]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Valverde]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ormaechea]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[NT-proBNP marcador biológico útil para monitorización del estado clínico y guía terapéutica en pacientes ambulatorios portadores de insuficiencia cardíaca sistólica]]></article-title>
<source><![CDATA[Arch Med Int]]></source>
<year>2010</year>
<volume>32</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>5-8</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valverde]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Acle]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ormaechea]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Grupo Colaborativo]]></surname>
<given-names><![CDATA[UMIC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[NT-ProBNP marcador biológico útil para monitorización del estado clínico y como factor pronóstico en pacientes ambulatorios portadores de insuficiencia cardíaca sistólica]]></article-title>
<source><![CDATA[Insuf Card]]></source>
<year>2013</year>
<volume>8</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>59-69</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stienen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Salah]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Moons]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Bakx]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[van Pol]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Kortz]]></surname>
<given-names><![CDATA[RAM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?)]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2018</year>
<volume>137</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>1671-83</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vishram]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic interactions between cardiovascular risk factors]]></article-title>
<source><![CDATA[Dan Med J]]></source>
<year>2014</year>
<volume>61</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>B4892</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Yoon]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Oh]]></surname>
<given-names><![CDATA[IY]]></given-names>
</name>
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk Factor Burden, Heart Failure, and Survival in Women of Different Ethnic Groups Insights From the Women&amp;apos;s Health Initiative]]></article-title>
<source><![CDATA[Circ Heart Fail]]></source>
<year>2018</year>
<volume>11</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Komajda]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Follath]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Swedberg]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Cleland]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen-Solal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe Part 2: treatment]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2003</year>
<volume>24</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>464-74</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crespo-Leiro]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Anker]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Maggioni]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Coats]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Filippatos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ruschitzka]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT) 1-year follow-up outcomes and differences across regions (published correction appears in Eur J Heart]]></article-title>
<source><![CDATA[Fail]]></source>
<year>2017</year>
<volume>19</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>438</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Komajda]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cowie]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Tavazzi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ponikowski]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Anker]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Filippatos]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Physicians&amp;apos; guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction the QUALIFY international registry]]></article-title>
<source><![CDATA[Eur J Heart Fail]]></source>
<year>2017</year>
<volume>19</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1414-23</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guglin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Awad]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
<name>
<surname><![CDATA[Polavaram]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Vankayala]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aldosterone antagonists the most underutilized class of heart failure medications]]></article-title>
<source><![CDATA[Am J Cardiovasc Drugs]]></source>
<year>2007</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>75-9</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alotaibi]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Alabdan]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Alotaibi]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Aljaafary]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Alqahtani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Utilization of Spironolactone in Heart Failure Patients at a Tertiary Hospital in Saudi Arabia]]></article-title>
<source><![CDATA[Cureus]]></source>
<year>2020</year>
<volume>12</volume>
<numero>8</numero>
<issue>8</issue>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Troughton]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Michael Felker]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Januzzi Jr]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Natriuretic peptide-guided heart failure management]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2014</year>
<volume>35</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>16-24</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sokhanvar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Shekhi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mazlomzadeh]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Golmohammadi]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Relationship between Serum NT- Pro-BNP Levels and Prognosis in Patients with Systolic Heart Failure]]></article-title>
<source><![CDATA[J Cardiovasc Thorac Res]]></source>
<year>2011</year>
<volume>3</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>57-61</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lupón]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Parajón]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Urrutia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzáleza]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Herrerosa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Altimiret]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reducción de los ingresos por insuficiencia cardíaca en el primer año de seguimiento en una unidad multidisciplinaria]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2005</year>
<volume>58</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>374-80</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kenchaiah]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Larson]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Benjamin]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kupka]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term trends in the incidence of and survival with heart failure]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2002</year>
<volume>347</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1397-402</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laribi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Aouba]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nikolaou]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lassus]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen-Solal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Plaisance]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trends in death attributed to heart failure over the past two decades in Europe]]></article-title>
<source><![CDATA[Eur J Heart Fail]]></source>
<year>2012</year>
<volume>14</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>234-9</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
